Saturday, November 13, 1999

* "TALKING" POSTER DISCUSSION GROUPS are organized discussions of selected poster presentations. During the "TALKING" POSTER DISCUSSION GROUP session, each presenter in the grouping has 5 minutes to present key findings/issues from his/her poster. A discussion leader will then address methodological or other issues common to the presentations as given in the title of the Discussion Group.

8.00 - 9.00	"TALKING" POSTERS DISPLAYED Attendees are encouraged to view posters BEFORE attendinng the Discussion Groups.
9.00 - 10.00	"TALKING" POSTERS DISCUSSION GROUPS* GROUP I - CONTRIBUTED PAPERS
QUALITY OF LIFE METHODOLOGY ISSUES
	TPQ1	THE EUROPEAN REGULATORY ISSUES ON QUALITY OF LIFE ASSESSMENT (ERIQA) PROJECT Acquadro C, Mapi Research Institute, Lyon, France, for the ERIQA Group
	TPQ2	A REVIEW OF AVAILABLE HEALTH-RELATED QUALITY OF LIFE (HRQL) REFERENCE VALUES IN THE MEDICAL LITERATURE Keininger DL, Conway K, Acquadro C, Anfray C, Mapi Research Institute, Lyon, France
	TPQ3	EUROPEAN GUIDANCE DOCUMENT FOR THE IMPROVEMENT OF THE INTEGRATION OF HEALTH-RELATED QUALITY OF LIFE (HRQL) ASSESSMENT IN THE DRUG REGULATORY PROCESS Chassany O1, Fullerton S23, Sagnier P4, Aaronson N5, Marquis P6 for the European Regulatory Issues on Quality of Life Assessment (ERIQA) group, 1Lariboisiere Hospital, Paris, France; 2Astra Hässle, Mölndal, Sweden; 3UCLA Department of Medicine, Los Angeles, CA, USA; 4Bayer AG, Leverkusen, Germany; 5The Netherlands Cancer Institute, Amsterdam, The Netherlands; 6MAPI Values, Lyon, France
	TPQ4	A EUROPEAN EQ-5D VALUE SET. MYTH OR REALITY? De Charro F, Weijnen T on behalf of all the participants in the EQ-net project, Institute for Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The Netherlands
	TPQ5	MAPI RESEARCH INSTITUTE HEALTH-RELATED QUALITY OF LIFE OUTCOMES DATABASE (IQOD) PROJECT Keininger DL1, Conway K1, Acquadro C1, Marquis P2, Jambon B1, 1Mapi Research Institute, Lyon, France; 2Mapi Values, Lyon, France
PHARMACY ISSUES
	TPP1	IMPLEMENTING A MODEL OF RISK SHARING OF PHARMACEUTICAL BENEFITS IN PRIMARY CARE Gilabert A, Casals A, Sedano E, Catalan Health Service, Autonomous Government of Catalonia, Barcelona, Spain
	TPP2	EVALUATION OF A THERAPEUTIC INTERCHANGE PROGRAM FOR CALCIUM CHANNEL BLOCKERS IN HYPERTENSION Nichol MB1, Harada ASM1, Jones J1, Gilderman A2, Salas J2, 1University of Southern California, Los Angeles, CA, USA; 2Prescription Solutions, Costa Mesa, CA, USA
	TPP3	PHARMACEUTICAL CARE AND HEALTH CARE UTILIZATION Fischer LR, DeFor T, Cooper S, Scott L, Boonstra D, Eelkema M, Hase K, Goodman M, HealthPartners, Minneapolis, MN, USA
	TPP4	POTENTIAL COST SAVINGS BY PRESCRIPTION OF THE CHEAPEST DRUGS AMONG THOSE WITH EQUAL CONTENT IN PRIMARY CARE Alegre de Rey E, Martinez Rodriguez L, Rabadan Asensio A, Pharmacy Unit, Cadiz-Bahia Primary Care Area, Cadiz, Spain
ECONOMIC MODELING STUDY ISSUES
	TPE1	ASSESSMENT OF THE APPROPRIATENESS OF CLINICAL GUIDELINES FOR CONTINUTATION TREATMENT IN MAJOR DEPRESSION FROM A HEALTH ECONOMIC PERSPECTIVE Nuijten MJC, MEDTAP International, Amsterdam, The Netherlands
	TPE2	ECONOMIC EVALUATION OF ENOXAPARIN AS POST DISCHARGE PROPHYLAXIS FOR DEEP VEIN THROMBOSIS (DVT) IN ELECTIVE HIP SURGERY Davies LM1, Richardson GA1, Cohen AT2, 1Centre for Health Economics, University of York, York, UK; 2Department of Medicine, Guys, Kings, Thomas's School of Medicine and Dentistry, Denmark Hill, London, UK
	TPE3	ECONOMIC EVALUATION OF DIFFERENT STRATEGIES OF A VACCINATION AGAINST HEPATITIS A AND HEPATITIS B Smala A1, Berger K1, Szucs T2, 1MERG - Medical Economics Research Group, Munich, Germany; 2UniversitätsSpital Zurich, Zurich, Switzerland
	TPE4	DEVELOPMENT OF A QUALITY ASSESSMENT CHECKLIST FOR THE APPRAISAL OF ECONOMIC MODELS A CASE-STUDY IN OSTEOPOROSIS Hege U1, Pang F2, Tolley K3, 1Department of Health Sciences, University of York, York, North Yorkshire, UK; 2Centre for Health Economics, University of York, York, North Yorkshire, UK; 3Pfizer Central Research, Sandwich, Kent, UK
	TPE5	COST OF MANAGING BENIGN PROSTATE HYPERPLASIA IN BELGIUM Annemans L12, Vanoverbeke N2, Closon MC3, 1Free University of Brussels, Brussels, Belgium; 2HEDM, Mechelen, Belgium; 3Université Catholique de Louvain, Brussels, Belgium
10.00 - 11.00	"TALKING" POSTERS DISCUSSION GROUPS* GROUP II - CONTRIBUTED PAPERS
ECONOMIC OBSERVATIONAL STUDY METHODOLOGY ISSUES
	TPM1	DIRECT AND INDIRECT COST OF MIGRAINE IN ITALY Arpinelli F, Manetta F, Roncolato M, Fabbri L, Rizzini P, Medical Directorate, Glaxo Wellcome S.p.A., Verona, Italy
	TPM2	ONE-YEAR REHOSPITALISATION RATE IN SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER Tavcar R, Dernovsek M, Zvan V, University Psychiatric Hospital, Ljubljana-Polje, Slovenia
	TPM3	THE EFFECT OF OBSERVATION DURATION ON CLAIMS-BASED RISK ADJUSTMENT SCORES Andrews K, Powell-Threets K, Zhao Z, Center for Outcomes Measurement and Performance Assessment, Merck-Medco Managed Care, L.L.C., Montvale, NJ, USA
	TPM4	EVALUATION OF HIV/AIDS TREATMENT REGIMENS AND CONCOMITANT THERAPY USING A LARGE PHARMACY CLAIMS DATABASE Hutchison S, Beno C, Information Operations, PCS Health Systems, Inc., Scottsdale, AZ, USA
	TPM5	BURDEN OF BRONCHIAL ASTHMA: FAMILY EXPENSES FOR CHILD`S DISEASE Prosekova E, Geltser B, Pashcenko O, Childhood Town Clinical Hospital, Vladivostok State Medical University, Vladivostok, Russia
RANDOMIZED CLINICAL STUDY METHODOLOGY ISSUES
	TPC1	COST-EFFECTIVENESS ANALYSIS OF BUDESONIDE VERSUS DISODIUM CROMOGLYCATE THERAPY IN CHILDREN WITH MODERATE BRONCHIAL ASTHMA Szende A1, Hoffer G2, Kelenhegyi K1, Cserhati E3, Spicak V4, 1AstraZeneca, Torokbalint, Hungary; 2DOTE School of Public Health, Debrecen, Hungary; 3Semmelweis Medical University, Budapest, Hungary; 4Faculti Nemocnice Bulovka, Prague, Czech Republic
	TPC2	COST-MINIMIZATION ANALYSIS OF TWO TRIPLE REGIMENS FOR THE TREATMENT OF HELICOBACTER PYLORI-RELATED PEPTIC ULCER DISEASE You JH1, Lee KKC1, Ho SSS1, Sung JJY2, Yung MY3, Lee CW1, Yee GCY4, 1Department of Pharmacy Practice, The Chinese University of Hong Kong, Hong Kong, China; 2Department of Pharmacy, Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China; 3Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China; 4University of Nebraska, Omaha, NE, USA
	TPC3	COST OF AML TREATMENT IN BELGIUM: RESULTS OF A RANDOMIZED TRIAL WITH AND WITHOUT FILGRASTIM USE Noens L1, Fillet G2, Zachée P3, Van Schoubroek K4, Standaert B4, 1UZ Gent, Gent, Belgium; 2CHU Sart Tilman, Liège, Belgium; 3AZ Stuyvenberg, Antwerpen, Belgium; 4Amgen, Brussels, Belgium
	TPC4	AN ECONOMIC EVALUATION OF AMLODIPINE FOR THE TREATMENT OF NONISCHEMIC DILATED CARDIOMYOPATHY: THE PROSPECTIVE RANDOMIZED AMLODIPINE SURVIVAL EVALUATION (PRAISE) Glick HA1, Polsky D1, Schulman KA2, Martin BC3, O'Connor CM4, 1University of Pennsylvania, Philadelphia, PA, USA; 2Georgetown University Medical Center, Washington, DC, USA; 3The University of Georgia, Athens, GA, USA; 4Duke University Medical Center, Durham, NC, USA
ECONOMIC EVALUATION METHODOLOGICAL ISSUES
	TPL1	STATE OF THE ART IN PHARMACOECONOMIC EVALUATION: A REVIEW OF METHODS AND PRACTICE Pang F1, Tolley K2, 1Centre for Health Economics, University of York, York, UK; 2Outcomes Research, Central Research, Pfizer, Sandwich, UK
	TPL2	MULTINATIONAL ECONOMIC EVALUATIONS: A REVIEW OF PUBLISHED STUDIES, METHODOLOGICAL ISSUES AND PRACTICE Pang F, Centre for Health Economics, University of York, York, UK
	TPL3	BEST EVIDENCE IN PHARMACOECONOMICS Mallarkey G, Venter-Lewis L, Adis International Ltd, Auckland, New Zealand
11.00 - 11.30	BREAK AND VIEWING OF "TALKING" POSTERS GROUP 1 AND II
11.30 - 12.000	THIRD GENERAL SESSION - SUPPLY AND DEMAND FOR TRAINING IN PHARMACECONOMICS AND OUTCOMES RESEARCH A REPORT OF THE ISPOR EUROPEAN EDUCATIONAL NEEDS ASSESSMENT SURVEY The results of the ISPOR European pharmacoeconomic and health outcomes educational needs assessment survey of pharmacy and medical clinical practitioners, government healthcare policy-makers, contract researchers and pharmaceutical industry personnel. This survey addressed the current skills of these groups and perceived training needs in the future as well as the knowledge and attitude about existing training in pharmacoeconomic and health care outcomes assessment.
12.00 - 13.00	LUNCH & EXHIBITS
13.00 - 13.50	THIRD GENERAL SESSION WORK GROUPS - SUPPLY AND DEMAND FOR TRAINING IN PHARMACEONOMICS AND OUTCOMES RESEARCH (CONTINUED) Participants will have the opportunity to discuss specific needs of pharmacy and medical clinincal practitioners (Work Group I), government healthcare policy-makers (Work Group II), contract researchers and pharmaceutical industry personnel (Work Group III). WORK GROUP I: Supply and demand for training by pharmacy and medical clinical practitioners Discussion Leaders: Francisco Batel Marques PharmD, School of Pharmacy, University of Coimbra, Coimbra, Portugal and Kim Brosen MD, PhD, University of Denmark, Copenhagen, Denmark WORK GROUP II: Supply and demand for Pharmacoeconomics training by government and other healthcare policy-makers Discussion Leader: TBD WORK GROUP III: Supply and demand for training by researchers in the pharmaceutical industry and research organizations Discussion Leaders: Bernard Genesté, Worldwide Senior Director, SocioEconomics, Rhône-Poulenc Rorer, Anthony Cedar, Rhône, France and John Hutton PhD, Senior Research Leader, MEDTAP International, London, United Kingdom
14.00 - 15.40	CONTRIBUTED PODIUM PRESENTATIONS - RESEARCH
ECONOMIC & OUTCOMES STUDY RESULTS OF CANCER
	CA1	PROSPECTIVE ECONOMIC EVALUATION OF ANTIBIOTIC PROPHYLAXIS IN SMALL CELL LUNG CANCER (SCLC) PATIENTS RECEIVING CHEMOTHERAPY Caleo S1, Tjan-Heijnen VGC2, Burghouts J3, Giaccone G4, 1EORTC Data Center, Brussels, Belgium; 2University Hospital, Nijmegen, The Netherlands; 3Groot Ziekenhasthuis, s'Hertogenbosch, The Netherlands; 4Academisch Ziekenhuis Der Vrije Universiteit Amsterdam, The Netherlands
	CA2	COST COMPARISONS BETWEEN HOSPITALS IN DIFFERENT COUNTRIES BY MEANS OF A RESOURCE USE INDEX Neymark N, Adriaenssen I, EORTC Health Economics Unit, Brussels, Belgium
	CA3	ESTIMATING SURVIVAL GAIN FOR COST-EFFECTIVENESS ANALYSIS: THE EXAMPLE OF EARLY HORMONAL TREATMENT IN LOCALLY ADVANCED PROSTATE CANCER Neymark N, Adriaenssen I, Caleo S, EORTC Health Economics Unit, Brussels, Belgium
	CA4	METASTATIC BREAST CANCER PATIENTS TREATED WITH DOCETAXEL Burrell A1, Hall A2, Eggleton SPH1, 1Rhône-Poulenc Rorer, Kent, UK; 2Centre for Medical and Dental Education, St Bartholomew's Hospital, London, UK
	CA5	QUALITY OF LIFE IN A BREAST CANCER POPULATION UNDERGOING ADJUVANT TREATMENT Nichol MB1, Venturini F1, Jones J1, Sherman G2, 1University of Southern California, Los Angeles, CA, USA; 2Cancer Care Associates, Torrance, CA, USA
QUALITY OF LIFE STUDY RESULTS
	QL1	THE QUALITY OF LIFE OF ESSENTIAL HYPERTENSIVES IN AN ECONOMICALLY DISADVANTAGED COMMUNITY: PREDICTORS AND RELEVANCE TO MANAGEMENT COMPLIANCE Golubev SA, Miliy MN, Shumann SG, Vitebsk State Medical University, Vitebsk, Belarus
	QL2	PSYCHOMETRIC EQUIVALENCE EVALUATION OF FIVE NON-WESTERN-LANGUAGE TRANSLATED VERSIONS OF THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY - GENERAL (FACT-G) VERSION 4 Eremenco S, Chang C-H, Lent L, Cella D, Center on Outcomes, Research, and Education (CORE), Evanston Northwestern Healthcare, Evanston, IL, USA
	QL3	ANTIPSYCHOTIC TREATMENT AND CHANGES IN HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA USING EQ-5D Badia X1, Casado A1, Sacristán JA2, Gómez JC2, Gregor KJ3, 1Public Health Institute of Catalonia, Barcelona, Spain; 2Eli Lilly and Company, Madrid, Spain; 3Eli Lilly and Company, Windlesham Surrey, UK
	QL4	USING RASCH MODELS TO IMPROVE THE EVALUATIVE-SCALE PROPERTIES OF THE WOMEN'S HEALTH QUESTIONNAIRE Turner R1, Hayes J1, Testa M2, 1Phase V Technologies, Inc., Wellesley Hills, MA, USA; 2Harvard School of Public Health, Boston, MA, USA
	QL5	ASTHMA BOTHER PROFILE VS. AIRWAY QUESTIONNAIRE 20 AS SIMPLE MEASURES TO EVALUATE THE HEALTH STATUS IN ASTHMA Nishimura K, Hajiro T, Tsukino M, Oga T, Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
STUDY RESULTS MEASURING SYMPTOMATIC RELIEF
	SR1	THE ECONOMIC IMPACT OF TOLTERODINE IN PORTUGAL Dias J1, Carvalho H2, 1Pharmacia & Upjohn Laboratórios Lda, Lisbon, Portugal; 2Portuguese Association of Neurourology and Urogynecology, Lisbon, Portugal
	SR2	A PHARMACO-ECONOMIC CASE STUDY IN ANAESTHESIA, INCLUDING A RECENT RE-ANALYSIS USING BOOTSTRAP TECHNIQUES McNamara J, Gillis S, Biostatistics Group, PAREXEL International, Sheffield, UK
	SR3	DEVELOPMENT AND VALIDATION OF THE QUALITY OF LIFE WITH MIGRAINE (QOLWM): A BRIEF MIGRAINE SURVEY Cramer JA1, Silberstein S2, Winner P3, Becker L4, Chmiel J4, Ashraf T4, Noble K4, 1Yale University School of Medicine, New Haven, CT, USA; 2Jefferson Headache Center, Philadelphia, PA, USA; 3Palm Beach Headache Center, West Palm Beach, FL, USA; 4Abbott Laboratories, Abbott Park, IL, USA
	SR4	LONGITUDINAL ASSESSMENT OF ASTHMA AND WORK OUTCOMES Erickson SR, Kirking DM, University of Michigan, Ann Arbor, MI, USA
	SR5	MEDICAL EVENTS AND RESOURCE UTILISATION IN CANCER PAIN PATIENTS TREATED WITH STRONG OPIOIDS : AN ANALYSIS OF THE UK-GPRD DATABASE Nuyts GD1, Haazen LM1, Jones MP2, 1Janssen Pharmaceutica, Beerse, Belgium; 2Jones and Just Pty Ltd, Sydney, Australia
15.40 - 17.00	CONTRIBUTED PODIUM PRESENTATIONS - RESEARCH
ECONOMIC & OUTCOMES STUDY RESULTS OF GASTROINTESTINAL DISORDERS
	GI1	COST-EFFECTIVENESS OF THE COMBINATION OF MISOPROSTOL WITH DICLOFENAC IN THE TAYSIDE POPULATION Morant S, Davey P, MacDonald T, Medicines Monitoring Unit (MEMO), Ninewells Hospital, Dundee, Scotland
	GI2	COST-EFFECTIVENESS ANALYSIS OF HIGH DOSE IV OMEPRAZOLE INFUSION AS ADJUVANT THERAPY TO ENDOSCOPIC HAEMOSTASIS FOR BLEEDING PEPTIC ULCERS Lee KKC1, You JH1, Lau JYW2, Sung JJY3,Yung MY2, Suk-San Ho S1, Lee CW1, Chung SSCC2, 1Department of Pharmacy, The Chinese University of Hong Kong, Hong Kong, China; 2Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China; 3Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
	GI3	EVALUATION OF PHARMACISTS' INTERVENTIONS ON PRESCRIBING ERRORS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: COSTS SAVINGS AND CLINICAL EFFECTS Cousin C, Misrahi L, Chamba G, Bauguil G, Colin C, Faculty of Pharmacy, Biological and Pharmaceutical Science Institute, Lyon, France
	GI4	PREDICTORS OF SAMPLE INCLUSION FOLLOWING THE APPLICATION OF CONTINUOUS ELIGIBILITY REQUIREMENTS IN SUBJECTS RECEIVING COLONOSCOPIES Bramley T1, Margraf T2, Okamoto L3, 1University of South Carolina, Columbia, SC, USA; 2PharMetrics Inc., Boston, MA, USA; 3NDC Health Information Services, Phoenix, AZ, USA
ECONOMIC ANALYSIS OF SERVICE DELIVERY
	SD1	USING CONJOINT ANALYSIS TO ASSESS WOMEN'S PREFERENCES FOR MATERNITY CARE SERVICES DURING THE INTRAPARTUM STAGE Ratcliffe J1, Longworth L1, Boulton M2, 1Health Economics Research Group, Brunel University, Uxbridge, UK; 2Department of Epidemiology and Public Health, Imperial College School of Medicine, London, UK
	SD2	GENERICS ONLY OR GENERICS AND EFFICIENT DRUGS? Bendahan G, Benaque A Direcció d'Atenció Primària Eixample, Institut Català de la Salut, Barcelona, Spain
	SD3	USING ECONOMIC INFORMATION IN HOSPITAL FORMULARY DECISION-MAKING Späth HM12, Ferdjaoui N12, Carrère MO12, 1GRESAC, Lyon, France; 2Université Lyon, Lyon, France
	SD4	QUALITY OF LIFE ASSESSMENT AS A NEW OUTCOME MEASURE IN CLINICAL PRACTICE Pratheepawanit N, Salek M, Finlay I, Luscombe D, Medicines Research Unit, Welsh School of Pharmacy and University of Wales College of Medicine, Cardiff, UK
ECONOMIC & OUTCOMES STUDY RESULTS OF ENDOCRINE DISORDERS
	ED1	COST-EFFECTIVENESS OF INTENSIVE METFORMIN VERSUS CONVENTIONAL THERAPY FOR OBESE PATIENTS WITH TYPE 2 DIABETES Palmer AJ1, Sendi PP1, Gozzoli V1, Brandt A1, Spinas GA2, 1IMIB, Institute for Medical Informatics and Biostatistics, Riehen, Switzerland; 2Division of Endocrinology and Diabetes, University Hospital, Zürich, Switzerland
	ED2	COST-EFFECTIVENESS OF ACROMEGALY TREATMENTS Wilson LS1, Shin JL2, Ezzat S2, 1Department of Pharmacy, University of California, San Francisco, CA, USA; 2Department of Medicine, University of Toronto, Toronto, Ontario, Canada
	ED3	DEALING WITH CO-MORBIDITY AND RARE COMPLICATIONS IN A DIABETES TYPE 2 COST OF ILLNESS STUDY Spannheimer A1, Goertz A2, Reitberger U1, Neiss A3, Liebl A4, 1Kendle GmbH & Co. GMI KG, Munich, Germany; 2SmithKline Beecham Pharma, Munich, Germany; 3Institute for Medical Statistics and Epidemiology at the Technical University, Munich, Germany; 4Diabetes Center Bogenhausen, Munich, Germany
	ED4	QUALITY OF LIFE AND USE OF HEALTHCARE RESOURCES IN GROWTH HORMONE-DEFICIENT ADULTS AFTER GROWTH HORMONE REPLACEMENT THERAPY Hernberg-Stâhl E1, Abs R2, Bengtsson B-A3, Feldt-Rasmussen U4, Monson JP5, Wilton P1, Wüster C6, 1Pharmacia & Upjohn, Stockholm, Sweden; 2University Hospital Antwerp, Egedem, Belgium; 3Sahlgrenska University Hospital, Göteborg, Sweden; 4Rigshospitalet, Copenhagen, Denmark; 5St. Bartholomew's Hospital, London, UK; 6University Hospital, Heidelberg, Germany
17.00 - 17.30	THIRD GENERAL SESSION - SUPPLY AND DEMAND FOR TRAINING IN PHARMACEONOMICS AND OUTCOMES RESEARCH (CONTINUED) WORK GROUP I REPORT WORK GROUP I REPORT WORK GROUP I REPORT